HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts.

Abstract
Tumor progression is promoted by Tumor-Associated Macrophages (TAMs) and metastasis-induced bone destruction by osteoclasts. Both myeloid cell types depend on the CD115-CSF-1 pathway for their differentiation and function. We used 3 different mouse cancer models to study the effects of targeting cancer host myeloid cells with a monoclonal antibody (mAb) capable of blocking CSF-1 binding to murine CD115. In mice bearing sub-cutaneous EL4 tumors, which are CD115-negative, the anti-CD115 mAb depleted F4/80(+) CD163(+) M2-type TAMs and reduced tumor growth, resulting in prolonged survival. In the MMTV-PyMT mouse model, the spontaneous appearance of palpable mammary tumors was delayed when the anti-CD115 mAb was administered before malignant transition and tumors became palpable only after termination of the immunotherapy. When administered to mice already bearing established PyMT tumors, anti-CD115 treatment prolonged their survival and potentiated the effect of chemotherapy with Paclitaxel. As shown by immunohistochemistry, this therapeutic effect correlated with the depletion of F4/80(+)CD163(+) M2-polarized TAMs. In a breast cancer model of bone metastasis, the anti-CD115 mAb potently blocked the differentiation of osteoclasts and their bone destruction activity. This resulted in the inhibition of cancer-induced weight loss. CD115 thus represents a promising target for cancer immunotherapy, since a specific blocking antibody may not only inhibit the growth of a primary tumor through TAM depletion, but also metastasis-induced bone destruction through osteoclast inhibition.
AuthorsLaetitia Fend, Nathalie Accart, Jacqueline Kintz, Sandrine Cochin, Carine Reymann, Fabrice Le Pogam, Jean-Baptiste Marchand, Thierry Menguy, Philippe Slos, Ronald Rooke, Sylvie Fournel, Jean-Yves Bonnefoy, Xavier Préville, Hélène Haegel
JournalPloS one (PLoS One) Vol. 8 Issue 9 Pg. e73310 ( 2013) ISSN: 1932-6203 [Electronic] United States
PMID24019914 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Receptor, Macrophage Colony-Stimulating Factor
Topics
  • Animals
  • Antibodies, Monoclonal (immunology, therapeutic use)
  • Bone Neoplasms (secondary)
  • Breast Neoplasms (pathology)
  • Cell Line, Tumor
  • Disease Models, Animal
  • Female
  • Heterografts
  • Humans
  • Macrophages (immunology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Nude
  • Neoplasms, Experimental (therapy)
  • Osteoclasts (immunology)
  • Receptor, Macrophage Colony-Stimulating Factor (immunology)
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: